Patient number | Sex | Age at diagnosis (years) | Disease duration (years) | Current medication | Anatomic site of biopsy sampling | IL-26 expression inflamed vs non-inflamed | IL-8 expression inflamed vs non-inflamed | IL-22 expression inflamed vs non-inflamed | |
Non-inflamed | Inflamed | ||||||||
CD1 | F | 21 | 16 | AZA, IFX | Caecum* | Terminal ileum* | 1.32 | 4.50 | 1.59 |
CD2 | M | 18 | 16 | Mesalazine, AZA | Descending colon | Descending colon | 8.30 | 11.67 | 3.67 |
CD3 | F | 25 | 15 | None | Colon | Colon | 2.31 | 1.50 | 0.32 |
CD4 | F | 28 | 1 | AZA | Caecum* | Terminal ileum* | 6.22 | 11.08 | 1.92 |
CD5 | F | 29 | 1 | Mesalazine, corticosteroids | Caecum* | Terminal ileum* | 1.12 | 1.52 | 1.50 |
CD6 | F | 29 | 22 | None | Descending colon | Descending colon | 0.52 | 1.41 | 2.81 |
CD7 | F | 18 | 5 | MTX | Caecum* | Terminal ileum/ileocaecal valve* | 15.03 | 31.12 | 13.58 |
CD8 | M | 36 | 17 | AZA | Transverse colon | Transverse colon | 0.85 | 2.24 | 3.07 |
CD9 | M | 50 | 1 | None | Ascending colon* | Terminal ileum* | 1.86 | 0.97 | ND |
CD10 | M | 36 | 17 | Corticosteroids | Caecum* | Terminal ileum* | 3.72 | 1.45 | 1.37 |
CD11 | M | 25 | 6 | AZA | Colon | Colon | 0.53 | 1.35 | ND |
CD12 | M | 26 | 7 | AZA | Caecum | Caecum | 0.29 | 4.26 | 3.35 |
Average (SEM) | 28.4 (2.6) | 10.3 (2.2) | Crohn’s disease | 3.52 (1.27) | 5.85 (2.55) | 3.32 (1.18) | |||
UC1 | F | 65 | 5 | Corticosteroids | Sigmoid* | Rectum* | 1.77 | 6.97 | 0.52 |
UC2 | M | 48 | 1 | Mesalazine, budenosid | Descending colon | Descending colon | 1.78 | 2.37 | 0.97 |
UC3 | M | 74 | 2 | AZA | rectum | Rectum | 0.78 | 0.94 | 0.72 |
UC4 | F | 39 | 5 | None | Transverse colon | Transverse colon | 2.75 | 2.01 | 3.25 |
UC5 | M | 39 | 3 | None | Caecum* | Rectum* | 8.66 | 8.12 | 5.74 |
UC6 | M | 57 | 6 | AZA, corticosteroids, mesalazine | Caecum | Caecum | 0.36 | 2.64 | ND |
UC7 | M | 36 | 6 | 6-MP | Sigmoid | Sigmoid | 1.63 | 5.82 | 1.82 |
UC8 | F | 34 | 4 | None | Sigmoid | Sigmoid | 5.73 | 3.27 | 2.42 |
UC9 | B | 34 | 8 | 6-MP, mesalazine, corticosteroids | Caecum* | Ascending colon* | 1.72 | 0.49 | 1.76 |
UC10 | M | 34 | 9 | MTX | Sigmoid* | Rectum* | 0.89 | 2.44 | 0.84 |
Average (SEM) | 46.0 (4.6) | 4.9 (0.8) | Ulcerative colitis | 2.61 (0.78) | 3.31 (0.83) | 2.00 (0.55) |
The current medical therapy and the anatomic site, from which the samples were taken, are given for all patients. Biopsy sampling for inflamed and non-inflamed lesions was aimed to be taken in the same colonic or ileal segment. This was not possible in patients marked with an asterisk due to severe inflammation in the whole anatomic segment. Therefore, biopsies from a bordering (non-inflamed) segment were included for comparison.
AZA, azathioprine; F, female; IFX, infliximab; M, male; 6-MP, 6-mercaptopurine; MTX, methotrexate; ND, not determined